Why Are Seagen Shares Sinking Today?

Loading...
Loading...

Seagen Inc SGEN reported Q4 revenues of $429.9 million, compared to $601.3 million a year ago, beating the consensus of $407.21 million.

  • Collaboration revenues for Q4 FY20 reflected license revenue related to ladiratuzumab vedotin and Tukysa agreements with Merck & Co Inc MRK
  • Net product sales increased 26% to $369.2 million, primarily attributable to Tukysa and Padcev. 
  • Royalty revenues increased 17% to $46 million primarily driven by sales of Adcetris outside the U.S. and Canada by Takeda Pharmaceutical Co Ltd TAK and, to a lesser extent, royalties from Polivy by Roche Holdings AG RHHBY and Blenrep by GlaxoSmithKline plc GSK, which are based on Seagen's technology.
  • Related: Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer.
  • The Company posted a Q4 EPS loss of $(0.95), missing the consensus of $(0.82).
  • Seagen held $2.2 billion in cash and investments.
  • Guidance: For FY22, Seagen expects total sales of $1.66 billion - $1.75 billion, below the consensus of $2.16 billion.
  • Outlook includes Adcetris sales of $730 million - $755 million (+5% Y/Y at midpoint), Padcev sales of $435 million - $455 million (+31% Y/Y) and Tukysa sales of $315 million - $335 million (almost flat).
  • Price Action: SGEN shares traded 15.8% lower at $119 during after-hours trading on Wednesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...